Jeff Yass’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-22,193
| Closed | -$71K | – | 14931 |
|
|
2022
Q2 | $71K | Buy |
22,193
+10,647
| +92% | +$41.5K | ﹤0.01% | 11767 |
|
|
2022
Q1 | $49K | Sell |
11,546
-36
| -0.3% | -$157 | ﹤0.01% | 12328 |
|
|
2021
Q4 | $54K | Buy |
+11,582
| New | +$48.3K | ﹤0.01% | 12508 |
|
|
2021
Q3 | – | Sell |
-50,722
| Closed | -$201K | – | 14191 |
|
|
2021
Q2 | $217K | Buy |
50,722
+24,925
| +97% | +$107K | ﹤0.01% | 11434 |
|
|
2021
Q1 | $109K | Sell |
25,797
-14,863
| -37% | -$81.9K | ﹤0.01% | 11817 |
|
|
2020
Q4 | $158K | Sell |
40,660
-741
| -2% | -$3.17K | ﹤0.01% | 10224 |
|
|
2020
Q3 | $167K | Sell |
41,401
-26,890
| -39% | -$111K | ﹤0.01% | 9613 |
|
|
2020
Q2 | $291K | Buy |
68,291
+18,853
| +38% | +$115K | ﹤0.01% | 8412 |
|
|
2020
Q1 | $208K | Sell |
49,438
-64,637
| -57% | -$408K | ﹤0.01% | 8617 |
|
|
2019
Q4 | $448K | Buy |
114,075
+90,190
| +378% | +$533K | ﹤0.01% | 7206 |
|
|
2019
Q3 | $210K | Buy |
+23,885
| New | +$226K | ﹤0.01% | 9009 |
|
|
2019
Q2 | – | Sell |
-14,199
| Closed | -$107K | – | 11363 |
|
|
2019
Q1 | $91K | Sell |
14,199
-15,851
| -53% | -$103K | ﹤0.01% | 8289 |
|
|
2018
Q4 | $283K | Buy |
+30,050
| New | +$452K | ﹤0.01% | 7119 |
|
|
2018
Q3 | – | Sell |
-18,027
| Closed | -$471K | – | 11010 |
|
|
2018
Q2 | $526K | Buy |
18,027
+1,105
| +7% | +$34.1K | ﹤0.01% | 6675 |
|
|
2018
Q1 | $504K | Buy |
+16,922
| New | +$546K | ﹤0.01% | 6623 |
|
|
2017
Q4 | – | Sell |
-204,939
| Closed | -$6.7M | – | 10524 |
|
|
2017
Q3 | $7.13M | Buy |
204,939
+194,613
| +1,885% | +$6.26M | ﹤0.01% | 2106 |
|
|
2017
Q2 | $307K | Buy |
+10,326
| New | +$296K | ﹤0.01% | 7557 |
|
|
2017
Q1 | – | Sell |
-20,446
| Closed | -$522K | – | 10983 |
|
|
2016
Q4 | $358K | Buy |
20,446
+2,206
| +12% | +$42.3K | ﹤0.01% | 7633 |
|
|
2016
Q3 | $434K | Buy |
18,240
+5,117
| +39% | +$96.4K | ﹤0.01% | 6333 |
|
|
2016
Q2 | $210K | Buy |
+13,123
| New | +$235K | ﹤0.01% | 7538 |
|
|
2016
Q1 | – | Sell |
-15,359
| Closed | -$274K | – | 10510 |
|
|
2015
Q4 | $415K | Buy |
15,359
+3,915
| +34% | +$107K | ﹤0.01% | 7120 |
|
|
2015
Q3 | $318K | Buy |
+11,444
| New | +$361K | ﹤0.01% | 7939 |
|
|
2015
Q2 | – | Sell |
-67,953
| Closed | -$1.4M | – | 10935 |
|
|
2015
Q1 | $1.24M | Buy |
+67,953
| New | +$1.38M | ﹤0.01% | 5321 |
|
Jeff Yass's LJPC Position: Q3 2022 in Review
Jeff Yass sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 22,193 shares — an estimated $71K sold.
Jeff Yass first reported a position in LJPC in Q1 2015 and held it in 23 quarters. The position peaked at $7.13M in Q3 2017. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Jeff Yass reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Jeff Yass sold 22,193 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $71K.
- Jeff Yass first reported a position in La Jolla Pharmaceutical Company in Q1 2015 and held it in 23 quarters.
- Jeff Yass's La Jolla Pharmaceutical Company position peaked at $7.13M in Q3 2017.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.